In this multicenter , randomized , double-blind , placebo-controlled study , we assessed larazotide acetate 0.5 , 1 , or 2 mg 3 times daily to relieve ongoing symptoms in 342 adults with CeD who had been on a GFD for 12 months or longer and maintained their current GFD during the study .